Nuotai Biotechnology, on the evening of June 6, the company announced that it had entered into an agreement with Nanjing Novozymes Biotech Co., Ltd. (hereinafter referred to as " Novozyme ") recently signed the " Synthetic Biology" in Nanjing Based on the synthetic biology technology platform and combining cross-cutting technologies such as organic synthesis and chemical processes, the two parties will jointly promote technological progress and project cooperation in the field of synthetic biology .

The company plans to jointly establish a biopharmaceutical company with Novagen , with the company holding 51% and Novagen holding 49%. After the establishment of the joint venture, it will be included in the company's consolidated financial statements, and will serve as a platform for subsequent cooperation and specific business. The specific investment scale, construction plan and other matters of the cooperation project will be separately agreed upon by both parties and the internal review procedures will be carried out, which is still uncertain. This investment does not constitute a related transaction, nor does it constitute a major asset reorganization.

From January to December 2024, the operating income structure of Notai Bio was as follows: pharmaceutical manufacturing accounted for 99.88%, and other businesses accounted for 0.12%.

https://finance.eastmoney.com/a/202506073424644162.html